Citations

Showing 10 of 108104 citations.

Liver Transplantation and Bariatric Surgery: Timing and Outcomes
Diwan, Tayyab S. , Rice, Teresa C. , Schauer, Daniel P. , Heimbach, Julie K.

Mayo Clinic

Liver Transplantation | August 7, 2018 | Volume: 24 | Issue: 9 | Pages: 1280-1287

10.1002/lt.25303 | PMID 30080949 Get It

Nonalcoholic steatohepatitis (NASH) is projected to become the leading indication for liver transplantation (LT) in the next decade in the United States. Strategies to treat the underlying etiology of NASH, which is almost always obesity, are being pursued. One such strategy is the utilization of bariatric surgery (BS) in the peritransplant period. The use of BS prior to LT could prevent the progression of NASH and abrogate the need for LT. BS at the time of LT or postoperatively has the potential to not only improve obesity‐associated conditions such as diabetes, but also the potential to influence the incidence of NASH in the post‐LT setting. However, there continues to be no consensus on the use and timing of BS in this patient population. This review aims to discuss the current literature and possible future action.
Posttraumatic Stress Disorder in Patients with Heavy Alcohol Consumption and Alcoholic Hepatitis
Samala, Niharika , Lourens, Spencer, Shah, Vijay H. , Kamath, Patrick S. , Crabb, David W. , Tang, Qing , Radaeva, Svetlana , Liangpunsakul, Suthat , Chalasani, Naga , Crabb, David W , Liangpunsakul, Suthat , Sanyal, Arun J.

Mayo Clinic

Alcoholism: Clinical and Experimental Research | August 7, 2018 | Volume: 42 | Issue: 10 | Pages: 1933-1938

10.1111/acer.13862 | PMID 30080255 Get It

BackgroundLifetime prevalence of posttraumatic stress disorder (PTSD) in the general population is reported to be 6.8%. Individuals with alcohol dependence and substance abuse have high prevalence of PTSD. However, the prevalence of PTSD in heavy drinkers with alcoholic hepatitis (AH) is not known.The study's aim was to determine the prevalence of PTSD in heavy drinkers with and without AH.MethodsWe screened for PTSD using the Primary Care‐PTSD questionnaire among heavy drinkers with (n = 115) and without (n = 64) AH participating in a multicenter observational study in which participants were followed up to 12 months following their enrollment.ResultsThe prevalence of PTSD in heavy drinkers with AH was 34% and was not different from heavy drinking controls without liver disease (34%). In the entire group screened for PTSD, the presence of PTSD was associated with higher alcohol consumption as reported by average drinks per last 30 days and average grams of alcohol consumed per day (p = 0.047 for both tests), but not associated with relapse of heavy drinking or mortality. Similarly, patients with AH and PTSD did not have higher relapse rate or higher mortality compared to patients with AH but no PTSD.ConclusionsCompared to previously reported prevalence in general population, heavy drinking individuals with or without AH have significantly higher prevalence of PTSD. However, PTSD was not associated with higher relapse rate or higher mortality in this population.
Comments on an Article by A.M. Malek et al.
Masters, David B.

Mayo Clinic

BioTechniques | August 7, 2018 | Volume: 23 | Issue: 4 | Pages: 672-674

10.2144/97234bf01 | PMID 9343692 Get It

Application of a Chimeric Green Fluorescent Protein to Study Protein-Protein Interactions
Garamszegi, Nandor, Garamszegi, Z.P., Rogers, Michael S. , DeMarco, Steven J. , Strehler, Emanuel E.

Mayo Clinic

BioTechniques | August 7, 2018 | Volume: 23 | Issue: 5 | Pages: 864-872

10.2144/97235st02 | PMID 9383552 Get It

In a Blinded Analysis, Restriction Endonuclease Fingerprinting Detects All the Mutations in a 1.9-kb Segment
Feng, Jinong, Sommer, Steve S., Liu, Qiang

Mayo Clinic

BioTechniques | August 7, 2018 | Volume: 23 | Issue: 5 | Pages: 836-839

10.2144/97235bm15 | PMID 9383547 Get It

Inhibition of PCR Amplification by a Point Mutation Downstream of a Primer
Thorland, Erik C., Sommer, Steve S., Liu, Qiang

Mayo Clinic

BioTechniques | August 7, 2018 | Volume: 22 | Issue: 2 | Pages: 292-300

10.2144/97222st01 | PMID 9043701 Get It

Targeting CD38 with daratumumab is lethal to Waldenström macroglobulinaemia cells
Paulus, Aneel , Manna, Alak , Akhtar, Sharoon , Paulus, Shumail M., Sharma, Mayank , Coignet, Marie V. , Jiang, Liuyan , Ansell, Stephen M. , Allan, John N. , Furman, Richard R. , Aulakh, Sonikpreet , Chanan‐Khan, Asher , Sher, Taimur , Manochakian, Rami , Ailawadhi, Sikander , Chanan-Khan, Asher A., Paulus, Aneel , Roy, Vivek , Witzig, Thomas E. , Ailawadhi, Sikander

Mayo Clinic

British Journal of Haematology | August 7, 2018 | Volume: 183 | Issue: 2 | Pages: 196-211

10.1111/bjh.15515 | PMID 30080238 Get It

SummaryCD38 is expressed on Waldenström macroglobulinaemia (WM) cells, but its role as a therapeutic target remains undefined. With recent approval of the anti‐CD38 monoclonal antibody, daratumumab (Dara), we hypothesized that blocking CD38 would be lethal to WM cells.In vitroDara treatment of WM cells (including ibrutinib‐resistant lines) elicited antibody‐dependent cellular cytotoxicity (ADCC), complement‐dependent cytotoxicity (CDC), antibody‐dependent cell phagocytosis (ADCP) and direct apoptosis.In vivo, Dara treatment was well tolerated and delayed tumour growth in RPCI‐WM1‐xenografted mice. CD38 is reported to augment B‐cell receptor (BCR) signalling; we noted that Dara significantly attenuated phosphorylated SYK, LYN, BTK, PLCγ2, ERK1/2, AKT, mTOR, and S6 levels, and this effect was augmented by cotreatment with ibrutinib. Indeed, WM cells, including ibrutinib‐resistant WM cell lines treated with the ibrutinib + Dara combination, showed significantly more cell death through ADCC, CDC, ADCP and apoptosis relative to single‐agent Dara or ibrutinib. In summary, we are the first to report thein vitroandin vivoanti‐WM activity of Dara. Furthermore, we show a close connection between BCR and CD38 signalling, which can be co‐targeted with ibrutinib + Dara to induce marked WM cell death, irrespective of acquired resistance to ibrutinib.
The MCL35 gene expression proliferation assay predicts high‐risk MCL patients in a Norwegian cohort of younger patients given intensive first line therapy
Holte, Harald , Beiske, Klaus , Boyle, Merrill, Trøen, Gunhild, Blaker, Yngvild Nuvin, Myklebust, June H. , Kvaløy, Sunniva, Rosenwald, Andreas , Rimsza, Lisa M. , Smeland, Erlend B., Kolstad, Arne , Rimsza, Lisa M , Holte, Harald , KVALOY, STEIN, Lingjærde, Ole Christian , Scott, David W.

Mayo Clinic

British Journal of Haematology | August 7, 2018 | Volume: 183 | Issue: 2 | Pages: 225-234

10.1111/bjh.15518 | PMID 30080252 Get It

SummaryPatients with mantle cell lymphoma (MCL) generally have a dismal prognosis. Intensified induction treatment with rituximab and high dose cytarabine (R_HDAC), and consolidation with high‐dose therapy with autologous stem cell support has resulted in 10‐year overall survival (OS) higher than 60%. However, the clinical course varies. Diagnostic tools capable of stratifying patients include the MCL International Prognostic Index (MIPI), gene expression‐based proliferation signature, Ki‐67 proliferation index or tumour cell morphology. Here, we tested the performance of a newly developed Nanostring‐based RNA expression‐based proliferation assay (MCL35) on formalin‐fixed paraffin‐embedded tumour tissue from younger patients recruited in or treated according to Nordic MCL protocols compared to the prognosticators listed above. Seventy‐four patients were included and the assay performed well in all cases except four, which had inadequate RNA quality. The patients were evenly distributed in the MCL35 low‐, intermediate‐ and high‐risk categories. MCL35 low‐ and intermediate‐ risk groups had overlapping progression‐free survival (PFS), while patients in the high‐risk category had significantly inferior PFS. Combining MCL35 with MIPI or the MIPI‐C (MIPI with the addition of binary Ki67 score +/−30%) showed a better discrimination than either assessment alone. In conclusion, the MCL35 assay alone or combined with MIPI or MIPI‐C scores can identify patients who still have a dismal outcome despite intensified treatment.
Detection and Characterization of Renal Stones by Using Photon-Counting–based CT
Marcus, Roy , Fletcher, Joel G. , Ferrero, Andrea , Leng, Shuai , Halaweish, Ahmed F., Gutjahr, Ralf , Vrtiska, Terri J., Wells, Mike L., McCollough, Cynthia H. , Marcus, Roy P, Enders, Felicity T, McCollough, Cynthia H , Fletcher, Joel G , Leng, Shuai , Enders, Felicity

Mayo Clinic

Radiology | August 7, 2018 | Volume: 289 | Issue: 2 | Pages: 436-442

10.1148/radiol.2018180126 | PMID 30084728 Get It

Establishing a Current Good Manufacturing Practice Facility for Biomaterials and Biomolecules in an Academic Medical Center
Greenberg, Alexandra J. , Runge, Bethany Kinseth, Solyntjes, Sarah A., Helene-Kraft, Juliana St., Glass, Suzanne L., Waletzki, Brian E., Herrick, James L., Yaszemski, Michael J. , Windebank, Anthony J. , Wang, Huan , Greenberg-Worisek, Alexandra J, St Helene-Kraft, Juliana, Miller, Alan Lee, Miller, Alan Lee , Wang, Huan

Mayo Clinic

Tissue Engineering Part B: Reviews | August 7, 2018 | Volume: 24 | Issue: 6 | Pages: 493-498

10.1089/ten.teb.2018.0114 | PMID 30084747 Get It